Traditional Approaches to Molecular Genetic Analysis

Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 943)

Abstract

Molecular studies of endometrial cancer have evolved with the tools available to researchers: the methods for measuring nucleic acids, protein expression, and combinations thereof. Today “molecular genetic analysis” implies a broad range of indirect and direct tests that yield molecular phenotypes or genotypes, immunotypes, or signatures that were not conceived of when the histologic and biologic heterogeneity was first fully acknowledged.

We will provide a historical perspective on molecular genetic studies of endometrial cancers focusing on candidate genes and how early foundational research shaped both our understanding of the disease and current research directions. Examples of direct tests (mutation, DNA methylation, and/or protein expression) will be provided along with examples of indirect tests that have been and continue to be central to endometrial cancer molecular biology, such as DNA content or microsatellite instability analysis. We will highlight clinically relevant examples of molecular phenotyping and direct evaluation of candidate genes that integrate direct and indirect testing as part of routine patient care. This is not intended to be an exhaustive review but rather an overview of the progress that has been made and how early work is shaping current molecular, clinical, and biologic studies of endometrial cancer.

Keywords

Indirect tests Direct tests Mutation testing Candidate genes Biologic relevance Clinical significance 

References

  1. 1.
    Sandritter W. Nucleic acid content of different neoplasms; adenocarcinomata, renal, thyroid, liver carcinoma and liver sarcoma. Frankf Z Pathol. 1952;63:432–46.PubMedGoogle Scholar
  2. 2.
    Harris H. Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris. Preface. J Cell Sci. 2008;121 Suppl 1:v–vi.PubMedGoogle Scholar
  3. 3.
    Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature. 1997;386:623–7.PubMedGoogle Scholar
  4. 4.
    Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 1991;51:3075–9.PubMedGoogle Scholar
  5. 5.
    McClelland SE, Burrell RA, Swanton C. Chromosomal instability A composite phenotype that influences sensitivity to chemotherapy. Cell Cycle. 2009;8:3262–6.PubMedGoogle Scholar
  6. 6.
    Mauland KK, Wik E, Salvesen HB. Clinical value of DNA content assessment in endometrial cancer. Cytometry B Clin Cytom. 2014;86:154–63.PubMedGoogle Scholar
  7. 7.
    Moberger B, Auer G, Forsslund G, et al. The prognostic significance of DNA measurements in endometrial carcinoma. Cytometry. 1984;5:430–6.PubMedGoogle Scholar
  8. 8.
    Auer G, Eriksson E, Azavedo E, et al. Prognostic significance of nuclear DNA content in mammary adenocarcinomas in humans. Cancer Res. 1984;44:394–6.PubMedGoogle Scholar
  9. 9.
    Salvesen HB, Akslen LA. Molecular pathogenesis and prognostic factors in endometrial carcinoma. APMIS. 2002;110:673–89.PubMedGoogle Scholar
  10. 10.
    Ionov Y, Peinado MA, Malkhosyan S, et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993;363:558–61.PubMedGoogle Scholar
  11. 11.
    Parsons R, Li GM, Longley MJ, et al. Hypermutability and mismatch repair deficiency in RER+ tumor cells. Cell. 1993;75:1227–36.PubMedGoogle Scholar
  12. 12.
    Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science. 1993;260:812–6.PubMedGoogle Scholar
  13. 13.
    Levinson G, Gutman GA. High frequencies of short frameshifts in poly-CA/TG tandem repeats borne by bacteriophage M13 in Escherichia coli K-12. Nucleic Acids Res. 1987;15:5323–38.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Strand M, Prolla TA, Liskay RM, et al. Destabilization of tracts of simple repetitive DNA in yeast by mutations affecting DNA mismatch repair. Nature. 1993;365:274–6.PubMedGoogle Scholar
  15. 15.
    Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell. 1993;75:1027–38.PubMedGoogle Scholar
  16. 16.
    Leach FS, Nicolaides NC, Papadopoulos N, et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell. 1993;75:1215–25.PubMedGoogle Scholar
  17. 17.
    Katabuchi H, van Rees B, Lambers AR, et al. Mutations in DNA mismatch repair genes are not responsible for microsatellite instability in most sporadic endometrial carcinomas. Cancer Res. 1995;55:5556–60.PubMedGoogle Scholar
  18. 18.
    Kowalski LD, Mutch DG, Herzog TJ, et al. Mutational analysis of MLH1 and MSH2 in 25 prospectively-acquired RER+ endometrial cancers. Genes Chromosomes Cancer. 1997;18:219–27.PubMedGoogle Scholar
  19. 19.
    Esteller M, Levine R, Baylin SB, et al. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene. 1998;17:2413–7.PubMedGoogle Scholar
  20. 20.
    Simpkins SB, Bocker T, Swisher EM, et al. MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet. 1999;8:661–6.PubMedGoogle Scholar
  21. 21.
    Kobayashi K, Matsushima M, Koi S, et al. Mutational analysis of mismatch repair genes, hMLH1 and hMSH2, in sporadic endometrial carcinomas with microsatellite instability. Jpn J Cancer Res. 1996;87:141–5.PubMedGoogle Scholar
  22. 22.
    Basil JB, Swisher EM, Herzog TJ, et al. Mutational analysis of the PMS2 gene in sporadic endometrial cancers with microsatellite instability. Gynecol Oncol. 1999;74:395–9.PubMedGoogle Scholar
  23. 23.
    Chen H, Taylor NP, Sotamaa KM, et al. Evidence for heritable predisposition to epigenetic silencing of MLH1. Int J Cancer. 2007;120:1684–8.PubMedGoogle Scholar
  24. 24.
    Raptis S, Mrkonjic M, Green RC, et al. MLH1–93G > A promoter polymorphism and the risk of microsatellite-unstable colorectal cancer. J Natl Cancer Inst. 2007;99:463–74.PubMedGoogle Scholar
  25. 25.
    Allan JM, Shorto J, Adlard J, et al. MLH1–93G > A promoter polymorphism and risk of mismatch repair deficient colorectal cancer. Int J Cancer. 2008;123:2456–9.PubMedGoogle Scholar
  26. 26.
    Whiffin N, Broderick P, Lubbe SJ, et al. MLH1-93G > A is a risk factor for MSI colorectal cancer. Carcinogenesis. 2011;32:1157–61.PubMedGoogle Scholar
  27. 27.
    Poplawski T, Sobczuk A, Sarnik J, et al. Polymorphism of DNA mismatch repair genes in endometrial cancer. Exp Oncol. 2015;37:44–7.PubMedGoogle Scholar
  28. 28.
    Savio AJ, Lemire M, Mrkonjic M, et al. MLH1 region polymorphisms show a significant association with CpG island shore methylation in a large cohort of healthy individuals. PLoS One. 2012;7:e51531.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer. 1993;71:677–85.PubMedGoogle Scholar
  30. 30.
    Wijnen J, De Leeuw W, Vasen H, et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet. 1999;23:142–4.PubMedGoogle Scholar
  31. 31.
    Goodfellow PJ, Buttin BM, Herzog TJ, et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A. 2003;100:5908–13.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Hampel H, Frankel W, Panescu J, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 2006;66:7810–7.PubMedGoogle Scholar
  33. 33.
    Buchanan DD, Tan YY, Walsh MD, et al. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. J Clin Oncol. 2014;32:90–100.PubMedGoogle Scholar
  34. 34.
    Goodfellow P, Billingsley CC, Lankes H, et al. Combined MSI, MLH1 methylation analysis and IHC for Lynch syndrome screening for 1002 endometrial cancers from GOG210: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2015;33(36):4301–8.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Lancaster JM, Powell CB, Chen LM, et al. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2015;136:3–7.PubMedGoogle Scholar
  36. 36.
    Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–57.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Kim GP, Colangelo LH, Wieand HS, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol. 2007;25:767–72.PubMedGoogle Scholar
  38. 38.
    Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28:3219–26.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Diaz-Padilla I, Romero N, Amir E, et al. Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2013;88:154–67.PubMedGoogle Scholar
  40. 40.
    Bilbao-Sieyro C, Ramirez R, Rodriguez-Gonzalez G, et al. Microsatellite instability and ploidy status define three categories with distinctive prognostic impact in endometrioid endometrial cancer. Oncotarget. 2014;5:6206–17.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73.PubMedGoogle Scholar
  42. 42.
    Larson JA. Estrogens and endometrial carcinoma. Obstet Gynecol. 1954;3:551–72.PubMedGoogle Scholar
  43. 43.
    Meissner WA, Sommers SC, Sherman G. Endometrial hyperplasia, endometrial carcinoma, and endometriosis produced experimentally by estrogen. Cancer. 1957;10:500–9.PubMedGoogle Scholar
  44. 44.
    Brush MG, Taylor RW, King RJ, et al. The uptake and metabolism of (6,7-3H)oestrediol by human endometrial carcinoma tissue in vivo and in vitro. J Endocrinol. 1968;41:12–3.PubMedGoogle Scholar
  45. 45.
    McCarty Jr KS, Barton TK, Fetter BF, et al. Correlation of estrogen and progesterone receptors with histologic differentiation in endometrial adenocarcinoma. Am J Pathol. 1979;96:171–83.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Kauppila A, Kujansuu E, Vihko R. Cytosol estrogen and progestin receptors in endometrial carcinoma of patients treated with surgery, radiotherapy, and progestin. Clinical correlates. Cancer. 1982;50:2157–62.PubMedGoogle Scholar
  47. 47.
    Kauppila AJ, Isotalo HE, Kivinen ST, et al. Prediction of clinical outcome with estrogen and progestin receptor concentrations and their relationships to clinical and histopathological variables in endometrial cancer. Cancer Res. 1986;46:5380–4.PubMedGoogle Scholar
  48. 48.
    Liao BS, Twiggs LB, Leung BS, et al. Cytoplasmic estrogen and progesterone receptors as prognostic parameters in primary endometrial carcinoma. Obstet Gynecol. 1986;67:463–7.PubMedGoogle Scholar
  49. 49.
    Siiteri PK. Steroid hormones and endometrial cancer. Cancer Res. 1978;38:4360–6.PubMedGoogle Scholar
  50. 50.
    Henderson BE, Ross RK, Pike MC, et al. Endogenous hormones as a major factor in human cancer. Cancer Res. 1982;42:3232–9.PubMedGoogle Scholar
  51. 51.
    Lentz SS, Brady MF, Major FJ, et al. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 1996;14:357–61.PubMedGoogle Scholar
  52. 52.
    Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17:1736–44.PubMedGoogle Scholar
  53. 53.
    Werner HM, Salvesen HB. Current status of molecular biomarkers in endometrial cancer. Curr Oncol Rep. 2014;16:403.PubMedGoogle Scholar
  54. 54.
    Budwit-Novotny DA, McCarty KS, Cox EB, et al. Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res. 1986;46:5419–25.PubMedGoogle Scholar
  55. 55.
    Snijders MP, De Goeij AF, Koudstaal J, et al. Is immunohistochemical analysis of oestrogen and progesterone receptors in endometrial carcinoma superior to the radioligand binding assay? J Pathol. 1990;161:129–35.PubMedGoogle Scholar
  56. 56.
    Segreti EM, Novotny DB, Soper JT, et al. Endometrial cancer: histologic correlates of immunohistochemical localization of progesterone receptor and estrogen receptor. Obstet Gynecol. 1989;73:780–5.PubMedGoogle Scholar
  57. 57.
    Gehrig PA, Van Le L, Olatidoye B, et al. Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. Cancer. 1999;86:2083–9.PubMedGoogle Scholar
  58. 58.
    Carcangiu ML, Chambers JT, Voynick IM, et al. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: clinical and histologic correlations. Am J Clin Pathol. 1990;94:247–54.PubMedGoogle Scholar
  59. 59.
    Chambers JT, Carcangiu ML, Voynick IM, et al. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part II: correlation between biochemical and immunohistochemical methods and survival. Am J Clin Pathol. 1990;94:255–60.PubMedGoogle Scholar
  60. 60.
    Kleine W, Maier T, Geyer H, et al. Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance. Gynecol Oncol. 1990;38:59–65.PubMedGoogle Scholar
  61. 61.
    Pertschuk LP, Masood S, Simone J, et al. Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. Gynecol Oncol. 1996;63:28–33.PubMedGoogle Scholar
  62. 62.
    Miyamoto T, Watanabe J, Hata H, et al. Significance of progesterone receptor-A and -B expressions in endometrial adenocarcinoma. J Steroid Biochem Mol Biol. 2004;92:111–8.PubMedGoogle Scholar
  63. 63.
    Sakaguchi H, Fujimoto J, Hong BL, et al. Drastic decrease of progesterone receptor form B but not A mRNA reflects poor patient prognosis in endometrial cancers. Gynecol Oncol. 2004;93:394–9.PubMedGoogle Scholar
  64. 64.
    Shabani N, Kuhn C, Kunze S, et al. Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer. 2007;43:2434–44.PubMedGoogle Scholar
  65. 65.
    Jongen V, Briet J, de Jong R, et al. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol. 2009;112:537–42.PubMedGoogle Scholar
  66. 66.
    Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996;392:49–53.PubMedGoogle Scholar
  67. 67.
    Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 2001;29:2905–19.PubMedPubMedCentralGoogle Scholar
  68. 68.
    Leygue E, Dotzlaw H, Watson PH, et al. Expression of estrogen receptor beta1, beta2, and beta5 messenger RNAs in human breast tissue. Cancer Res. 1999;59:1175–9.PubMedGoogle Scholar
  69. 69.
    Rutherford T, Brown WD, Sapi E, et al. Absence of estrogen receptor-beta expression in metastatic ovarian cancer. Obstet Gynecol. 2000;96:417–21.PubMedGoogle Scholar
  70. 70.
    Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer. 2011;11:597–608.PubMedGoogle Scholar
  71. 71.
    Waters KM, Safe S, Gaido KW. Differential gene expression in response to methoxychlor and estradiol through ERalpha, ERbeta, and AR in reproductive tissues of female mice. Toxicol Sci. 2001;63:47–56.PubMedGoogle Scholar
  72. 72.
    Lindberg MK, Moverare S, Skrtic S, et al. Estrogen receptor (ER)-beta reduces ERalpha-regulated gene transcription, supporting a “ying yang” relationship between ERalpha and ERbeta in mice. Mol Endocrinol. 2003;17:203–8.PubMedGoogle Scholar
  73. 73.
    Frasor J, Barnett DH, Danes JM, et al. Response-specific and ligand dose-dependent modulation of estrogen receptor (ER) alpha activity by ERbeta in the uterus. Endocrinology. 2003;144:3159–66.PubMedGoogle Scholar
  74. 74.
    Bjornstrom L, Sjoberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol. 2005;19:833–42.PubMedGoogle Scholar
  75. 75.
    Moore JT, McKee DD, Slentz-Kesler K, et al. Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun. 1998;247:75–8.PubMedGoogle Scholar
  76. 76.
    Poola I, Speirs V. Expression of alternatively spliced estrogen receptor alpha mRNAs is increased in breast cancer tissues. J Steroid Biochem Mol Biol. 2001;78:459–69.PubMedGoogle Scholar
  77. 77.
    Kastner P, Krust A, Turcotte B, et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 1990;9:1603–14.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Wei LL, Gonzalez-Aller C, Wood WM, et al. 5'-Heterogeneity in human progesterone receptor transcripts predicts a new amino-terminal truncated “C”-receptor and unique A-receptor messages. Mol Endocrinol. 1990;4:1833–40.PubMedGoogle Scholar
  79. 79.
    Wei LL, Miner R. Evidence for the existence of a third progesterone receptor protein in human breast cancer cell line T47D. Cancer Res. 1994;54:340–3.PubMedGoogle Scholar
  80. 80.
    Samalecos A, Gellersen B. Systematic expression analysis and antibody screening do not support the existence of naturally occurring progesterone receptor (PR)-C, PR-M, or other truncated PR isoforms. Endocrinology. 2008;149:5872–87.PubMedGoogle Scholar
  81. 81.
    Petitjean A, Achatz MI, Borresen-Dale AL, et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007;26:2157–65.PubMedGoogle Scholar
  82. 82.
    Okamoto A, Sameshima Y, Yamada Y, et al. Allelic loss on chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus. Cancer Res. 1991;51:5632–5.PubMedGoogle Scholar
  83. 83.
    Yaginuma Y, Westphal H. Analysis of the p53 gene in human uterine carcinoma cell lines. Cancer Res. 1991;51:6506–9.PubMedGoogle Scholar
  84. 84.
    Kohler MF, Berchuck A, Davidoff AM, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res. 1992;52:1622–7.PubMedGoogle Scholar
  85. 85.
    Enomoto T, Fujita M, Inoue M, et al. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res. 1993;53:1883–8.PubMedGoogle Scholar
  86. 86.
    Kohler MF, Nishii H, Humphrey PA, et al. Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias. Am J Obstet Gynecol. 1993;169:690–4.PubMedGoogle Scholar
  87. 87.
    Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol. 1995;26:1268–74.PubMedGoogle Scholar
  88. 88.
    Jia L, Liu Y, Yi X, et al. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res. 2008;14:2263–9.PubMedGoogle Scholar
  89. 89.
    Tsuda H, Hirohashi S. Frequent occurrence of p53 gene mutations in uterine cancers at advanced clinical stage and with aggressive histological phenotypes. Jpn J Cancer Res. 1992;83:1184–91.PubMedGoogle Scholar
  90. 90.
    Reinartz JJ, George E, Lindgren BR, et al. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol. 1994;25:1075–83.PubMedGoogle Scholar
  91. 91.
    Inoue M, Okayama A, Fujita M, et al. Clinicopathological characteristics of p53 overexpression in endometrial cancers. Int J Cancer. 1994;58:14–9.PubMedGoogle Scholar
  92. 92.
    Ito K, Watanabe K, Nasim S, et al. Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res. 1994;54:4667–70.PubMedGoogle Scholar
  93. 93.
    Soong R, Knowles S, Williams KE, et al. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br J Cancer. 1996;74:562–7.PubMedPubMedCentralGoogle Scholar
  94. 94.
    Geisler JP, Geisler HE, Wiemann MC, et al. p53 expression as a prognostic indicator of 5-year survival in endometrial cancer. Gynecol Oncol. 1999;74:468–71.PubMedGoogle Scholar
  95. 95.
    Stelloo E, Bosse T, Nout RA, et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol. 2015;28(6):836–44.PubMedGoogle Scholar
  96. 96.
    Jones MH, Koi S, Fujimoto I, et al. Allelotype of uterine cancer by analysis of RFLP and microsatellite polymorphisms: Frequent loss of heterozygosity on chromosome amrs 3p, 9q, 10q, and 17p. Genes Chromosomes Cancer. 1994;9:119–23.PubMedGoogle Scholar
  97. 97.
    Peiffer SL, Herzog TJ, Tribune DJ, et al. Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers. Cancer Res. 1995;55:1922–6.PubMedGoogle Scholar
  98. 98.
    Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science. 1997;275:1943–7.PubMedGoogle Scholar
  99. 99.
    Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15:356–62.PubMedGoogle Scholar
  100. 100.
    Kong D, Suzuki A, Zou TT, et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet. 1997;17:143–4.PubMedGoogle Scholar
  101. 101.
    Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997;57:3935–40.PubMedGoogle Scholar
  102. 102.
    Risinger JI, Hayes K, Maxwell GL, et al. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res. 1998;4:3005–10.PubMedGoogle Scholar
  103. 103.
    Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000;92:924–30.PubMedGoogle Scholar
  104. 104.
    Zhou XP, Kuismanen S, Nystrom-Lahti M, et al. Distinct PTEN mutational spectra in hereditary non-polyposis colon cancer syndrome-related endometrial carcinomas compared to sporadic microsatellite unstable tumors. Hum Mol Genet. 2002;11:445–50.PubMedGoogle Scholar
  105. 105.
    Monte NM, Webster KA, Neuberg D, et al. Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer. Cancer Res. 2010;70:6225–32.PubMedPubMedCentralGoogle Scholar
  106. 106.
    Salvesen HB, MacDonald N, Ryan A, et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer. 2001;91:22–6.PubMedGoogle Scholar
  107. 107.
    Zysman MA, Chapman WB, Bapat B. Considerations when analyzing the methylation status of PTEN tumor suppressor gene. Am J Pathol. 2002;160:795–800.PubMedPubMedCentralGoogle Scholar
  108. 108.
    Sobczuk A, Smolarz B, Romanowicz-Makowska H, et al. MMAC/PTEN gene expression in endometrial cancer: RT-PCR studies. Pol J Pathol. 2006;57:137–40.PubMedGoogle Scholar
  109. 109.
    Norimatsu Y, Moriya T, Kobayashi TK, et al. Immunohistochemical expression of PTEN and beta-catenin for endometrial intraepithelial neoplasia in Japanese women. Ann Diagn Pathol. 2007;11:103–8.PubMedGoogle Scholar
  110. 110.
    Kapucuoglu N, Aktepe F, Kaya H, et al. Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index. Pathol Res Pract. 2007;203:153–62.PubMedGoogle Scholar
  111. 111.
    Sarmadi S, Izadi-Mood N, Sotoudeh K, et al. Altered PTEN expression; a diagnostic marker for differentiating normal, hyperplastic and neoplastic endometrium. Diagn Pathol. 2009;4:41.PubMedPubMedCentralGoogle Scholar
  112. 112.
    Lacey Jr JV, Mutter GL, Ronnett BM, et al. PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. Cancer Res. 2008;68:6014–20.PubMedPubMedCentralGoogle Scholar
  113. 113.
    Baak JP, Van Diermen B, Steinbakk A, et al. Lack of PTEN expression in endometrial intraepithelial neoplasia is correlated with cancer progression. Hum Pathol. 2005;36:555–61.PubMedGoogle Scholar
  114. 114.
    Pavlakis K, Messini I, Vrekoussis T, et al. PTEN-loss and nuclear atypia of EIN in endometrial biopsies can predict the existence of a concurrent endometrial carcinoma. Gynecol Oncol. 2010;119:516–9.PubMedGoogle Scholar
  115. 115.
    Podsypanina K, Ellenson LH, Nemes A, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A. 1999;96:1563–8.PubMedPubMedCentralGoogle Scholar
  116. 116.
    Stambolic V, Tsao MS, Macpherson D, et al. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res. 2000;60:3605–11.PubMedGoogle Scholar
  117. 117.
    You MJ, Castrillon DH, Bastian BC, et al. Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc Natl Acad Sci U S A. 2002;99:1455–60.PubMedPubMedCentralGoogle Scholar
  118. 118.
    Wang H, Douglas W, Lia M, et al. DNA mismatch repair deficiency accelerates endometrial tumorigenesis in Pten heterozygous mice. Am J Pathol. 2002;160:1481–6.PubMedPubMedCentralGoogle Scholar
  119. 119.
    Kim TH, Franco HL, Jung SY, et al. The synergistic effect of Mig-6 and Pten ablation on endometrial cancer development and progression. Oncogene. 2010;29:3770–80.PubMedPubMedCentralGoogle Scholar
  120. 120.
    Chen ML, Xu PZ, Peng XD, et al. The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev. 2006;20:1569–74.PubMedPubMedCentralGoogle Scholar
  121. 121.
    Vilgelm A, Lian Z, Wang H, et al. Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+/- mice. Cancer Res. 2006;66:3375–80.PubMedGoogle Scholar
  122. 122.
    Begum M, Tashiro H, Katabuchi H, et al. Neonatal estrogenic exposure suppresses PTEN-related endometrial carcinogenesis in recombinant mice. Lab Invest. 2006;86:286–96.PubMedGoogle Scholar
  123. 123.
    Daikoku T, Hirota Y, Tranguch S, et al. Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Res. 2008;68:5619–27.PubMedPubMedCentralGoogle Scholar
  124. 124.
    Joshi A, Miller Jr C, Baker SJ, et al. Activated mutant p110alpha causes endometrial carcinoma in the setting of biallelic Pten deletion. Am J Pathol. 2015;185:1104–13.PubMedPubMedCentralGoogle Scholar
  125. 125.
    van der Zee M, Jia Y, Wang Y, et al. Alterations in Wnt-beta-catenin and Pten signalling play distinct roles in endometrial cancer initiation and progression. J Pathol. 2013;230:48–58.PubMedGoogle Scholar
  126. 126.
    Lindberg ME, Stodden GR, King ML, et al. Loss of CDH1 and Pten accelerates cellular invasiveness and angiogenesis in the mouse uterus. Biol Reprod. 2013;89:8.PubMedPubMedCentralGoogle Scholar
  127. 127.
    Cheng H, Liu P, Zhang F, et al. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. Cancer Res. 2014;74:15–23.PubMedGoogle Scholar
  128. 128.
    Lin YG, Shen J, Yoo E, et al. Targeting the glucose-regulated protein-78 abrogates Pten-null driven AKT activation and endometrioid tumorigenesis. Oncogene. 2015;34(43):5418–26.PubMedPubMedCentralGoogle Scholar
  129. 129.
    Yaginuma Y, Yamashita T, Ishiya T, et al. Abnormal structure and expression of PTEN/MMAC1 gene in human uterine cancers. Mol Carcinog. 2000;27:110–6.PubMedGoogle Scholar
  130. 130.
    Oh WK, George DJ, Kantoff PW. Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma: report of four cases. Cancer. 2002;94:686–9.PubMedGoogle Scholar
  131. 131.
    Uegaki K, Kanamori Y, Kigawa J, et al. PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma. Oncol Rep. 2005;14:389–92.PubMedGoogle Scholar
  132. 132.
    Kimura F, Watanabe J, Hata H, et al. PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. J Cancer Res Clin Oncol. 2004;130:161–8.PubMedGoogle Scholar
  133. 133.
    Dellas A, Jundt G, Sartorius G, et al. Combined PTEN and p27kip1 protein expression patterns are associated with obesity and prognosis in endometrial carcinomas. Clin Cancer Res. 2009;15:2456–62.PubMedGoogle Scholar
  134. 134.
    Erkanli S, Kayaselcuk F, Kuscu E, et al. Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium. Int J Gynecol Cancer. 2006;16:1412–8.PubMedGoogle Scholar
  135. 135.
    Athanassiadou P, Athanassiades P, Grapsa D, et al. The prognostic value of PTEN, p53, and beta-catenin in endometrial carcinoma: a prospective immunocytochemical study. Int J Gynecol Cancer. 2007;17:697–704.PubMedGoogle Scholar
  136. 136.
    Mackay HJ, Gallinger S, Tsao MS, et al. Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG). Eur J Cancer. 2010;46:1365–73.PubMedGoogle Scholar
  137. 137.
    Akiyama-Abe A, Minaguchi T, Nakamura Y, et al. Loss of PTEN expression is an independent predictor of favourable survival in endometrial carcinomas. Br J Cancer. 2013;109:1703–10.PubMedPubMedCentralGoogle Scholar
  138. 138.
    Kanamori Y, Kigawa J, Itamochi H, et al. PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy. Int J Cancer. 2002;100:686–9.PubMedGoogle Scholar
  139. 139.
    Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer. 2003;10:203–8.PubMedGoogle Scholar
  140. 140.
    Fernandez-Medarde A, Santos E. Ras in cancer and developmental diseases. Genes Cancer. 2011;2:344–58.PubMedPubMedCentralGoogle Scholar
  141. 141.
    Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11:761–74.PubMedPubMedCentralGoogle Scholar
  142. 142.
    Agnantis NJ, Spandidos DA, Mahera H, et al. Immunohistochemical study of ras oncogene expression in endometrial and cervical human lesions. Eur J Gynaecol Oncol. 1988;9:360–5.PubMedGoogle Scholar
  143. 143.
    Long CA, O’Brien TJ, Sanders MM, et al. ras oncogene is expressed in adenocarcinoma of the endometrium. Am J Obstet Gynecol. 1988;159:1512–6.PubMedGoogle Scholar
  144. 144.
    Lester DR, Cauchi MN. Point mutations at codon 12 of C-K-ras in human endometrial carcinomas. Cancer Lett. 1990;51:7–10.PubMedGoogle Scholar
  145. 145.
    Enomoto T, Inoue M, Perantoni AO, et al. K-ras activation in neoplasms of the human female reproductive tract. Cancer Res. 1990;50:6139–45.PubMedGoogle Scholar
  146. 146.
    Enomoto T, Inoue M, Perantoni AO, et al. K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res. 1991;51:5308–14.PubMedGoogle Scholar
  147. 147.
    Ignar-Trowbridge D, Risinger JI, Dent GA, et al. Mutations of the Ki-ras oncogene in endometrial carcinoma. Am J Obstet Gynecol. 1992;167:227–32.PubMedGoogle Scholar
  148. 148.
    Duggan BD, Felix JC, Muderspach LI, et al. Early mutational activation of the c-Ki-ras oncogene in endometrial carcinoma. Cancer Res. 1994;54:1604–7.PubMedGoogle Scholar
  149. 149.
    Fujimoto I, Shimizu Y, Hirai Y, et al. Studies on ras oncogene activation in endometrial carcinoma. Gynecol Oncol. 1993;48:196–202.PubMedGoogle Scholar
  150. 150.
    Boyd J, Risinger JI. Analysis of oncogene alterations in human endometrial carcinoma: prevalence of ras mutations. Mol Carcinog. 1991;4:189–95.PubMedGoogle Scholar
  151. 151.
    Sasaki H, Nishii H, Takahashi H, et al. Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res. 1993;53:1906–10.PubMedGoogle Scholar
  152. 152.
    Swisher EM, Peiffer-Schneider S, Mutch DG, et al. Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability. Cancer. 1999;85:119–26.PubMedGoogle Scholar
  153. 153.
    Lax SF, Kendall B, Tashiro H, et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer. 2000;88:814–24.PubMedGoogle Scholar
  154. 154.
    Xiong J, He M, Jackson C, et al. Endometrial carcinomas with significant mucinous differentiation associated with higher frequency of k-ras mutations: a morphologic and molecular correlation study. Int J Gynecol Cancer. 2013;23:1231–6.PubMedGoogle Scholar
  155. 155.
    Sawyers CL. Finding and drugging the vulnerabilities of RAS-dependent cancers. Cell. 2009;137:796–8.PubMedGoogle Scholar
  156. 156.
    Ostrem JM, Peters U, Sos ML, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503:548–51.PubMedPubMedCentralGoogle Scholar
  157. 157.
    Maurer T, Garrenton LS, Oh A, et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A. 2012;109:5299–304.PubMedPubMedCentralGoogle Scholar
  158. 158.
    Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res. 2012;18:5856–64.PubMedGoogle Scholar
  159. 159.
    Carter EP, Fearon AE, Grose RP. Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction. Trends Cell Biol. 2015;25: 221–33.PubMedGoogle Scholar
  160. 160.
    Teven CM, Farina EM, Rivas J, et al. Fibroblast growth factor (FGF) signaling in development and skeletal diseases. Genes Dis. 2014;1:199–213.PubMedPubMedCentralGoogle Scholar
  161. 161.
    Stephens P, Edkins S, Davies H, et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet. 2005;37:590–2.PubMedGoogle Scholar
  162. 162.
    Bardelli A, Parsons DW, Silliman N, et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science. 2003;300:949.PubMedGoogle Scholar
  163. 163.
    Ruhe JE, Streit S, Hart S, et al. Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res. 2007;67:11368–76.PubMedGoogle Scholar
  164. 164.
    Pollock PM, Gartside MG, Dejeza LC, et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene. 2007;26:7158–62.PubMedPubMedCentralGoogle Scholar
  165. 165.
    Byron SA, Gartside MG, Wellens CL, et al. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res. 2008;68:6902–7.PubMedGoogle Scholar
  166. 166.
    Taniguchi F, Harada T, Sakamoto Y, et al. Activation of mitogen-activated protein kinase pathway by keratinocyte growth factor or fibroblast growth factor-10 promotes cell proliferation in human endometrial carcinoma cells. J Clin Endocrinol Metab. 2003;88:773–80.PubMedGoogle Scholar
  167. 167.
    Shukla V, Coumoul X, Wang RH, et al. RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis. Nat Genet. 2007;39:1145–50.PubMedGoogle Scholar
  168. 168.
    Wilkie AO. Cancer drugs to treat birth defects. Nat Genet. 2007;39:1057–9.PubMedGoogle Scholar
  169. 169.
    Dutt A, Salvesen HB, Chen TH, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A. 2008;105:8713–7.PubMedPubMedCentralGoogle Scholar
  170. 170.
    Byron SA, Loch DC, Pollock PM. Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells. Int J Gynecol Cancer. 2012;22:1517–26.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyOhio State University Comprehensive Cancer CenterColumbusUSA

Personalised recommendations